Will new AR inhibitors reshape the prostate cancer landscape?

Affiliations

¹ Service d'Urologie, Institut de Recherche Clinique (IREC), Université Catholique de Louvain, 1200 Brussels, Belgium. Electronic address: Bertrand.tombal@uclouvain.be.

Comment

Bertrand Tombal. Lancet Oncol. 2014 Aug.

. 2014 Aug;15(9):912-3.

doi: 10.1016/S1470-2045(14)70292-X. Epub 2014 Jun 25.

¹ Service d'Urologie, Institut de Recherche Clinique (IREC), Université Catholique de Louvain, 1200 Brussels, Belgium. Electronic address: Bertrand.tombal@uclouvain.be.

No abstract available

Comment on

Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
Fizazi K, Massard C, Bono P, Jones R, Kataja V, James N, Garcia JA, Protheroe A, Tammela TL, Elliott T, Mattila L, Aspegren J, Vuorela A, Langmuir P, Mustonen M; ARADES study group. Fizazi K, et al. Lancet Oncol. 2014 Aug;15(9):975-85. doi: 10.1016/S1470-2045(14)70240-2. Epub 2014 Jun 25. Lancet Oncol. 2014. PMID: 24974051 Clinical Trial.